Aflibercept (Eylea)

Aflibercept (Eylea) is covered for FDA‑approved ophthalmic indications (neovascular AMD, macular edema from RVO, DME, DR) and select compendial off‑label uses (neovascular glaucoma, retinopathy of prematurity, sickle cell neovascularizations, choroidal neovascular conditions); other uses are not covered. Approvals are for up to 12 months and require administration by or under an ophthalmologist with documentation of the listed diagnosis and adherence to the policy’s indication‑specific intravitreal dosing schedules (e.g., 2 mg q4wk×3 then q8wk for AMD; q4wk for RVO; q4wk×5 then q4–8wk for DME/DR; ≤2 mg q4wk for off‑label uses).

"Neovascular (wet) age-related macular degeneration (AMD)"

Sign up to see full coverage criteria, indications, and limitations.